Scarica l'app Stockscreener
27.14
2.09%
-0.58
Dopo l'orario di chiusura:
27.06
-0.08
-0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - Monroe Evening News
Moderna Inc. Stock Advances 5.5%, Outperforms Peers - 富途牛牛
How Moderna Inc. (MRNA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Why Moderna Might Be a One-Hit Wonder - The Globe and Mail
Why Moderna Might Be a One-Hit Wonder - The Motley Fool
Intraday pattern recognizer results for Moderna Inc.Quarterly Trade Summary & Step-by-Step Trade Execution Guides - newser.com
Leerink Partners Adjusts Price Target on Moderna to $16 From $15, Maintains Underperform Rating - MarketScreener
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note - sharewise.com
Moderna: Q3 Earnings PreviewI Fear A Halloween Horror Show (Downgrade) (NASDAQ:MRNA) - Seeking Alpha
Lobbying Update: $80,000 of MODERNA US INC. lobbying was just disclosed - Quiver Quantitative
Moderna (MRNA) Tops List of Most Shorted S&P 500 Stocks - GuruFocus
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Norwich Bulletin
How to use Fibonacci retracement on Moderna Inc.July 2025 Spike Watch & Low Volatility Stock Recommendations - newser.com
Key facts: Moderna faces cash flow challenges; stock rises on therapy data - TradingView
Moderna (MRNA) Stock Trades Up, Here Is Why - The Globe and Mail
Moderna’s Off-The-Shelf Cancer Immunotherapy Shows Early Promise - insights.citeline.com
Is Moderna Inc. meeting your algorithmic filter criteriaRate Hike & Fast Exit Strategy with Risk Control - newser.com
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients - Benzinga
Moderna (MRNA) Unveils Promising Data on mRNA-4359 for Melanoma Treatment - GuruFocus
What’s next for Moderna Inc. stock priceJuly 2025 Highlights & Consistent Growth Stock Picks - newser.com
Moderna (MRNA) Tops Healthcare Short Interest Rankings - GuruFocus
Respiratory Syncytial Virus (RSV) Market Explosion To hit - openPR.com
Moderna Claims Early Victory for Cancer Antigen in Melanoma - BioSpace
Moderna, Inc. (MRNA) Stock Analysis: Navigating Volatility With A 65% Potential Upside - DirectorsTalk Interviews
Moderna reports early cancer therapy data at medical conference - StreetInsider
KLP Kapitalforvaltning AS Sells 34,400 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Janney Montgomery Scott LLC - MarketBeat
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress - Times Herald
Moderna says it presents promising early data for investigational cancer antigen therapy - MarketScreener
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans - Shreveport Times
Moderna (NASDAQ:MRNA) Given New $32.00 Price Target at Morgan Stanley - MarketBeat
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - Yahoo Finance
MRNA: Morgan Stanley Raises Price Target for Moderna | MRNA Stoc - GuruFocus
Covid-19 Vaccine Recommendations | Moderna - OurQuadCities
Moderna assists with the evolving landscape of COVID-19 vaccine - KHGI
AstraZeneca ups investment in Virginia; Moderna vets launch VC fund - BioPharma Dive
Moderna (NASDAQ:MRNA) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Newport Daily News
Should Moderna's (MRNA) Improved Revenue Trends Prompt New Action From Investors? - Yahoo Finance
Is Moderna Inc. trending in predictive chart modelsRate Hike & Daily Stock Trend Reports - newser.com
Moderna, Inc. $MRNA Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Best Biotech Stocks To Follow NowOctober 6th - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
GSK Doesn't Have To Explain COVID Vax Claims For Moderna - Law360
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing - sharewise.com
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):